A leaders-style argument says US policymakers should not restrict Chinese biotechnology, citing patient access to faster and cheaper treatments as evidence of the practical downside of broad licensing or trial skepticism. The piece points to a bill that would amend the COINS Act to include licensing Chinese biotech and suggests a push for the FDA to disregard clinical-trial data from China. The article frames the debate as a tradeoff between national-security controls and clinical evidence utilization. It also underscores how regulatory willingness to accept international data can become politically charged. For biotech companies with China-linked collaborations, the coverage signals a heightened compliance and strategy risk: regulatory and investment constraints may evolve quickly, affecting trial planning and commercial pathways.